|
gptkbp:instanceOf
|
gptkb:drug
cannabinoid receptor antagonist
|
|
gptkbp:ATCCode
|
gptkb:A08AX01
|
|
gptkbp:CASNumber
|
gptkb:168273-06-1
|
|
gptkbp:category
|
anorectic
anti-obesity drug
carboxamide
chloroarene
pyrazole
|
|
gptkbp:chemicalFormula
|
gptkb:C22H21Cl3N4O
|
|
gptkbp:contraindication
|
psychiatric disorders
history of depression
|
|
gptkbp:countryWithdrawing
|
gptkb:Brazil
gptkb:European_Union
gptkb:Mexico
United States (never approved)
|
|
gptkbp:developedBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:effect
|
improves metabolic parameters
reduces appetite
reduces body weight
|
|
gptkbp:eliminationHalfLife
|
6-9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstApproval
|
2006 (EU)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rimonabant
|
|
gptkbp:indication
|
weight loss
smoking cessation (investigational)
|
|
gptkbp:intendedUse
|
anti-obesity agent
|
|
gptkbp:IUPACName
|
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
|
|
gptkbp:legalStatus
|
withdrawn
|
|
gptkbp:mechanismOfAction
|
CB1 receptor antagonist
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2C9)
|
|
gptkbp:molecularWeight
|
463.8 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1507
94613
104850
|
|
gptkbp:retired
|
psychiatric side effects
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
anxiety
suicidal ideation
|
|
gptkbp:synonym
|
gptkb:Acomplia
gptkb:SR141716
gptkb:Zimulti
|
|
gptkbp:target
|
gptkb:cannabinoid_receptor_type_1_(CB1)
|
|
gptkbp:UNII
|
N9U1B1K3TI
|
|
gptkbp:withdrawn
|
2008
|
|
gptkbp:bfsParent
|
gptkb:CB1
|
|
gptkbp:bfsLayer
|
6
|